Supported by an educational grant from Takeda
TITLE - Hereditary Angioedema: An Overview of Clinical Considerations & Advances in Treatment
TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, ED Pharmacists, ED Nurses, and Nurses
LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, ED Pharmacists, ED Nurses, and Nurses
- Describe the pathophysiology and epidemiology of hereditary angioedema (HAE)
- Recognize the types of HAE
- List the symptoms and clinical presentation of HAE
- Identify differential diagnosis of HAE
- Discuss the importance of early diagnosis of HAE and screening in patients who are at high risk
- Describe currently available treatment options for HAE and updated guidelines
- Discuss considerations in special populations of patients with HAE
- Explain strategies to counsel and educate patients about HAE and its treatment and management
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Faculty Disclosure: Mark Malesker, PharmD, FCCP, FCCM, FASHP, BCPS, has no relevant conflicts of interest to disclose. He does not intend to discuss non-FDA approved drugs or investigational use of any product/device.
Pharmacist continuing education credit
Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Knowledge Based Activity
Course release date 9/30/2020
Course expires 9/30/2023
Nursing continuing education credit
Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Course release date: 10/4/2020
Course expires: 10/4/2022
|Activity Number||Credit Amount||Accreditation Period|
|0535-0000-20-010-H01-P||0.15 CEUs||September 30, 2020 - September 30, 2023|
|0535-0000-20-010-H01-N||1.5 hours of CNE||October 04, 2020 - October 04, 2022|